


18-04634-E



Julia Justusson
ktMINE
940 West Adams
Suite 100
Chicago, IL 60607

6/7/2018

U.S. Securities & Exchange Commission
Office of FOIA and Privacy Act Operations
100 F Street, NE
Mail Stop 2465
Washington, DC 20549-5100

Dear Sir or Madam:

Under the Freedom of Information Act (FOIA), please send the confidential portions (i.e. unredacted documents) corresponding to the expiration of the Confidential Treatment Order submitted under Rule 24b-2 of the following company:

Exhibit 10.29 to the form S-1/A filed by MAP Pharmaceuticals, Inc. on August 20, 2007.

We authorize \$0 for search and review fees, as these documents have been previously requested. Please contact me if search will require additional fees beyond the above mentioned. I can be reached via email at julia.justusson@ktmine.com.

Sincerely,

A handwritten signature in black ink, appearing to read "Julia Justusson".

Julia Justusson



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
STATION PLACE
100 F STREET, NE
WASHINGTON, DC 20549-2465

Office of FOIA Services

June 21, 2018

Ms. Julia Justusson
ktMINE
940 West Adams, Suite 100
Chicago, IL 60607

RE: Freedom of Information Act (FOIA), 5 U.S.C. § 552
Request No. 18-04634-E

Dear Ms. Justusson:

This letter is in response to your request, dated and received in this office on June 7, 2018, for Exhibit 10.29 to the Form S-1/A filed by MAP Pharmaceuticals, Inc. on August 20, 2007.

Your request is granted in full. The 5-page exhibit is enclosed with this letter. Because this exhibit was released in response to a previous FOIA request, no processing fees have been assessed.

If you have any questions, please contact me at Gbenoua@sec.gov or (202) 551-5327. You may also contact me at foiapa@sec.gov or (202) 551-7900. You also have the right to seek assistance from Jeffery Ovall as a FOIA Public Liaison or contact the Office of Government Information Services (OGIS) for dispute resolution services. OGIS can be reached at 1-877-684-6448 or Archives.gov or via e-mail at ogis@nara.gov.

Sincerely,

Amy Gbenou

Amy Gbenou
FOIA Research Specialist

Enclosure

EXHIBIT 10.29

SECOND AMENDMENT TO LICENSE AGREEMENT

This SECOND AMENDMENT ("**Second Amendment**") is made and entered into as of this 18th day of June, 2007 ("**Second Amendment to License Agreement Effective Date**").

BETWEEN:

- (1) **Elan Pharma International Limited**, a company incorporated under the laws of Ireland, and having its registered office at Monksland, Athlone, County Westmeath, Ireland ("**EPIL**"); and
- (2) **MAP Pharmaceuticals, Inc.**, a company incorporated under the laws of Delaware, having its principal place of business at 2400 Bayshore Parkway, Suite 2000, Mountain View, CA 94043, USA ("**MAP**").

RECITALS:

WHEREAS, EPIL and MAP entered into a license agreement on February 3, 2005 whereby EPIL granted to MAP an exclusive sublicensable license to EPIL Intellectual Property for the sole purpose of, and only to the extent necessary for, using, marketing, distributing, selling, having sold, offering for sale, importing and exporting the Product in the Field in the Territory ("**License Agreement**"), which was subsequently amended in writing by the parties on September 15, 2006 ("**First Amendment**"). (License Agreement and First Amendment collectively referred to herein as the "**Agreement**")

WHEREAS, the EPIL Intellectual Property licensed in the Agreement relate to certain EPIL Patents, set out in Schedule 1 of the Agreement;

WHEREAS, the Parties now wish to amend the scope of the EPIL Patents listed in Schedule 1 of the Agreement as set forth below;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, EPIL and MAP hereby agree as follows:

1. Schedule 1 of the Agreement is hereby deleted and replaced by Schedule 1 affixed hereto.
2. All other terms and conditions of the Agreement remain unchanged and continue to be in full force and effect.
3. Capitalized terms not defined in this Second Amendment shall have the same meaning as set forth in the Agreement.
4. This Second Amendment may be signed in any number of counterparts with the same effect as if the signatures to each counterpart were upon a single instrument, and

all such counterparts together shall be deemed an original of this Second Amendment Agreement.

5. This Second Amendment shall be governed by and construed solely in accordance with the laws of the State of New York, without regard to its conflict of laws principles that would require the application of any other law.

IN WITNESS WHEREOF EPIL AND MAP have caused this Second Amendment to be executed by their duly authorized representatives as of the Second Amendment Effective Date.

ELAN PHARMA INTERNATIONAL LIMITED

By: /s/ Shane Cooke

Title: Director

Date: June 18, 2007

MAP PHARMACEUTICALS, INC.

By: /s/ Timothy Nelson

Title: President and CEO

Date: June 13, 2007

SCHEDULE 1 EPIL PATENTS

Title of Invention	Country	Patent/Appln. No.
Gamma Irradiation of Solid Nanoparticulate Active Agents	U.S.	Appln. No. 10/654,600
Liquid Droplet Aerosols of Nanoparticulate Drugs	U.S.	Patent No. 6,811,767
Use of Purified Surface Modifiers to Prevent Particle Aggregation During Sterilization	U.S.	Patent No. 5,352,459
Surface Modified Drug Nanoparticles	U.S.	Patent No. 5,145,684
	Argentina	Patent No. AR 255241
	Australia	Patent No. 654836
	Canada	Patent No. 2,059,432
	Chile	Appln. No. 92/074
	Columbia	Patent No. 24635
	Europe	Patent No. EP 499 299
	Austria	Validation of EP 499 299
	Belgium	Validation of EP 499 299
	Denmark	Validation of EP 499 299
	France	Validation of EP 499 299
	Germany	Validation of EP 499 299
	Greece	Validation of EP 499 299
	Italy	Validation of EP 499 299
	Luxembourg	Validation of EP 499 299
	Monaco	Validation of EP 499 299
	Netherlands	Validation of EP 499 299
	Portugal	Validation of EP 499 299
	Spain	Validation of EP 499 299
	Sweden	Validation of EP 499 299
	Switzerland	Validation of EP 499 299
	Great Britain	Validation of EP 499 299
	Finland	Patent No. 108333
	Hungary	Patent No. 221,586
	Ireland	Appln. No. 92-0217
	Israel	Patent. No. 100754
	Japan	Appln. No. 92/11226
	South Korea	Patent No. 200061
	Malaysia	Patent No. MY-108134-A
	Mexico	Patent No. 176345
	New Zealand	Patent No. 241362
	Norway	Patent No. 303668
	Philippines	Patent No. 29069
	Russia	Patent No. 2066553
	Singapore	Patent No. 55104
	Taiwan	Patent No. NI-071312
The Use of Tyloxapol as a Nanoparticle Stabilizer and Dispersant	U.S.	Patent No. 5,429,824
	Australia	Patent No. 665669
	Canada	Appln. No. 2,108,192
	Europe	Patent No. EP 602702
	France	Validation of EP 602702

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Title of Invention	Country	Patent/Appln. No.
Method of Grinding Pharmaceutical Substances	Germany	Validation of EP 602702
	Italy	Validation of EP 602702
	Great Britain	Validation of EP 602702
	Japan	Appln. No. 280799/93
	South Korea	Patent No. 320390
	Philippines	Patent No. 29957
	U. S.	Patent No. 5,518,187
	Argentina	Patent No. 251001
	Australia	Patent No. 660852
	Canada	Appln. No. 2,107,400
	Taiwan	Patent No. NI-69476
	Czech Republic	Patent No. 284802
	Europe	Patent No. EP 600528
	Netherlands	Validation of EP 600528
	Sweden	Validation of EP 600528
	Portugal	Validation of EP 600528
	Monaco	Validation of EP 600528
	Belgium	Validation of EP 600528
	Switzerland	Validation of EP 600528
	Germany	Validation of EP 600528
Process of Preparing Therapeutic Compositions Containing Nanoparticles	Denmark	Validation of EP 600528
	Spain	Validation of EP 600528
	France	Validation of EP 600528
	Great Britain	Validation of EP 600528
	Greece	Validation of EP 600528
	Ireland	Validation of EP 600528
	Italy	Validation of EP 600528
	Liechtenstein	Validation of EP 600528
	Luxembourg	Validation of EP 600528
	Austria	Validation of EP 600528
	Finland	Patent No. 108399
	Hungary	Patent No. 210928
	Japan	Appln. No. 2002-250972
	South Korea	Patent No. 312798
	Malaysia	Patent No. MY-109,419-A
	Mexico	Patent No. 189779
	New Zealand	Patent No. 248813
	Norway	Appln. No. 93-03719
	Philippines	Patent No. 31118
	Slovak Republic	Patent No. 281078
Pharmaceutical Compositions Containing Polyalkylene Block Copolymers Which Gel at Physiological Temperature	Ukraine	Appln. No. 93/3406
	Venezuela	Patent No. 1484-93
	U.S.	Patent No. 5,510,118
	U.S.	Patent No. 5,565,188
	U.S.	Patent No. 5,705,194
	Canada	Appln. No. 2,213,663
	Europe	Patent No. EP 810 855
	Germany	Validation of EP 810 855
	United Kingdom	Validation of EP 810 855
	France	Validation of EP 810 855
	Italy	Validation of EP 810 855
	Japan	Appln. No. 8-525803

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Title of Invention	Country	Patent/Appln. No.
Butylene Oxide-Ethylene Oxide Block Copolymer Surfactants as Stabilizer Coatings for Nanoparticle Compositions	U.S.	Patent No. 5,587,143
	Canada	Appln. No. 2,193,503
	Europe	Patent No. EP 804 162
	Germany	Validation of EP 804 162
	France	Validation of EP 804 162
	Great Britain	Validation of EP 804 162
	Italy	Validation of EP 804 162
	Israel	Patent No. 114354
	Japan	Appln. No. 503205/96
Aerosols Containing Nanoparticulate Dispersions	U.S.	Patent No. 6,264,922
	U.S.	Appln. No. 09/577,489
	Canada	Appln. No. 2,213,638
	Europe	Appln. No. 96906566.3 (EP 810 853)
	Japan	Appln. No. 8-525798
Methods for Preventing Crystal Growth and Particle Aggregation in Nanoparticle Compositions	U.S.	Patent No. 6,267,989
	Japan	Appln. No. 2000-603653
	Canada	Patent No. 2,367,096
	Europe	Patent No. EP 1 161 229
	France	Validation of EP 1 161 229
	Great Britain	Validation of EP 1 161 229
	Germany	Validation of EP 1 161 229
Sterile Filtered Nanoparticulate Formulations of Budesonide and Beclomethasone Having Tyloxapol as a Surface Stabilizer	U.S.	Appln. No. 10/035,324
	PCT	Appln. No. US02/41768
Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization	U.S.	Patent No. 5,346,702
Use of ionic cloud point modifiers to prevent particle aggregation during sterilization	U.S.	Patent No. 5,298,262
Method of preparing nanoparticle compositions containing charged phospholipids to reduce aggregation	U.S.	Patent No. 5,470,583
Sterilized Nanoparticulate Glucocorticosteroid Formulations	U.S.	Patent Appln. No. Appln. No. 11/275,775
Sterilization of Dispersions of Nanoparticulate Active Agents with Gamma Radiation	U.S.	Appln. No. 10/851,661
	Japan	Appln. No. 100102978
	Canada	Appln. No. 2,523,035
	European Patent	Appln. No. 04751758.6
	U.S.	Patent No. 6,267,989
Methods for Preventing Crystal Growth and Particle Aggregation in Nanoparticle Compositions	Japan	Appln. No. 2000-603653
	Canada	Patent No. 2,367,096
	European Patent	Patent No. EP 1 161 229
	France	Validation of EP 1 161 229
	Great Britain	Validation of EP 1 161 229
	Germany	Validation of EP 1 161 229
	Italy	Validation of EP 1 161 229

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.